ESMO 2019 | TNBC treatment: platinum-based therapy and PARP inhibition

Véronique Dieras

Véronique Dieras, MD, Eugène Marquis Center, Rennes, France, talks about BRCA mutations in triple-negative breast cancer (TNBC) and the promising response to cytotoxic platinum-based chemotherapy and PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video